{
  "first_published_at": "2011-09-07", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON128953", 
  "title": "Antipsychotics: use during third trimester of pregnancy and extrapyramidal effects or withdrawal symptoms in newborns", 
  "tags": "{\"parsed_therapeutic\": [\"obstetrics-gynaecology-fertility\", \"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Obstetrics, gynaecology and fertility\", \"Psychiatry\"]}", 
  "_document_number": 138, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "obstetrics-gynaecology-fertility", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Antipsychotics: use during third trimester of pregnancy and extrapyramidal effects or withdrawal symptoms in newborns</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>A recent Europe-wide review has concluded that there is a risk of extrapyramidal effects or withdrawal symptoms (or both) in newborns after maternal use of antipsychotics during the third trimester of pregnancy. This conclusion is based on worldwide post-marketing case reports and information provided by the US Food and Drugs Administration</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>There are insufficient data to determine the size of the risk or any difference in risk between classes of antipsychotics or between individual antipsychotics.</p><p>UK product information for all antipsychotics will be updated to include consistent information about this risk.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Following maternal use of antipsychotics in the third trimester, examine&nbsp; newborns for symptoms which may include: agitation; hypertonia; hypotonia; tremor; somnolence; feeding problems; and respiratory distress</li>\r\n\t\t\t\t<li>Symptoms may vary in severity and duration, and they should be monitored and treated (if necessary) on an individual basis</li>\r\n\t\t\t\t<li>Expectant mothers should be counselled about the benefits and risks of antipsychotic treatment during pregnancy</li>\r\n\t\t\t</ul></div><p>Please report suspected adverse events related to the use of antipsychotics during pregnancy through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a></p><p>&nbsp;</p><p><strong>Further information:</strong></p><p>Report from the <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109581.pdf\" target=\"_blank\">European Pharmacovigilance Working Party</a>&nbsp;</p><p>US Food and Drug Administration safety <a href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm\" target=\"_blank\">information on antipsychotic drugs and treatment during pregnancy</a>&nbsp;</p><p><a href=\"http://www.emc.medicines.org.uk/\" target=\"_blank\">Summaries of Product Characteristics</a></p><p>BNF section 4.2.1 <a href=\"http://bnf.org/bnf/bnf/61/3209.htm?q=antipsychotics&t=search&ss=text&p=3\" target=\"_blank\">Antipsychotic drugs</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Sept 2011, vol 5 issue&nbsp;2: A2.</em>&nbsp;<br></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>There are insufficient data to determine the size of the risk or any difference in risk between classes of antipsychotics or between individual antipsychotics.</p><p>UK product information for all antipsychotics will be updated to include consistent information about this risk.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Following maternal use of antipsychotics in the third trimester, examine&#160; newborns for symptoms which may include: agitation; hypertonia; hypotonia; tremor; somnolence; feeding problems; and respiratory distress</li>\r\n\t\t\t\t<li>Symptoms may vary in severity and duration, and they should be monitored and treated (if necessary) on an individual basis</li>\r\n\t\t\t\t<li>Expectant mothers should be counselled about the benefits and risks of antipsychotic treatment during pregnancy</li>\r\n\t\t\t</ul></div><p>Please report suspected adverse events related to the use of antipsychotics during pregnancy through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a></p><p>&#160;</p><p><strong>Further information:</strong></p><p>Report from the <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109581.pdf\" target=\"_blank\">European Pharmacovigilance Working Party</a>&#160;</p><p>US Food and Drug Administration safety <a href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm\" target=\"_blank\">information on antipsychotic drugs and treatment during pregnancy</a>&#160;</p><p><a href=\"http://www.emc.medicines.org.uk/\" target=\"_blank\">Summaries of Product Characteristics</a></p><p>BNF section 4.2.1 <a href=\"http://bnf.org/bnf/bnf/61/3209.htm?q=antipsychotics&amp;t=search&amp;ss=text&amp;p=3\" target=\"_blank\">Antipsychotic drugs</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Sept 2011, vol 5 issue&#160;2: A2.</em>&#160;<br></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-09-01", 
  "date_last_modified": "2011-09-07", 
  "_assets": [], 
  "_item_id": 138, 
  "summary": "A recent Europe-wide review has concluded that there is a risk of extrapyramidal effects or withdrawal symptoms (or both) in newborns after maternal use of antipsychotics during the third trimester of pregnancy. This conclusion is based on worldwide post-marketing case reports and information provided by the US Food and Drugs Administration", 
  "body": "Article date: September 2011\n\nThere are insufficient data to determine the size of the risk or any difference in risk between classes of antipsychotics or between individual antipsychotics.\n\nUK product information for all antipsychotics will be updated to include consistent information about this risk.\n\nAdvice for healthcare professionals:  \n  \n  * Following maternal use of antipsychotics in the third trimester, examine  newborns for symptoms which may include: agitation; hypertonia; hypotonia; tremor; somnolence; feeding problems; and respiratory distress  \n  * Symptoms may vary in severity and duration, and they should be monitored and treated (if necessary) on an individual basis  \n  * Expectant mothers should be counselled about the benefits and risks of antipsychotic treatment during pregnancy  \n  \nPlease report suspected adverse events related to the use of antipsychotics during pregnancy through the Yellow Card Scheme at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk)\n\n \n\nFurther information:\n\nReport from the [European Pharmacovigilance Working Party](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109581.pdf) \n\nUS Food and Drug Administration safety [information on antipsychotic drugs and treatment during pregnancy](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm) \n\n[Summaries of Product Characteristics](http://www.emc.medicines.org.uk/)\n\nBNF section 4.2.1 [Antipsychotic drugs](http://bnf.org/bnf/bnf/61/3209.htm?q=antipsychotics&t=search&ss=text&p=3)\n\n \n\nArticle citation: Drug Safety Update Sept 2011, vol 5 issue 2: A2.   \n\n"
}